Cargando…

An elusive case of systemic mastocytosis

Detalles Bibliográficos
Autores principales:	Lee, JK, Vadas, P
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874294/ http://dx.doi.org/10.1186/1710-1492-6-S1-P24

Ejemplares similares

Adverse reactions to food in patients with mastocytosis
por: Pucino, Valentina, et al.
Publicado: (2011)

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

Association of mastocytosis with interleukin 31 gene polymorphism
por: Nedoszytko, Boguslaw, et al.
Publicado: (2015)

Fishing for elusive cCMP-degrading phosphodiesterases
por: Schneider, Erich, et al.
Publicado: (2013)

Basophil Activation Test in the prediction of anaphylactic reactions against Hymenoptera venom in patients suffering from Systemic Mastocytosis
por: Rietveld, Mark JA, et al.
Publicado: (2012)

P21 - Evaluation of modifications in SCORMA Index and grading in the follow-up of a pediatric population with mastocytosis
por: Del Mastro, Andrea, et al.
Publicado: (2014)

Mastocytosis in the skin in children and adults
por: Lange, Magdalena
Publicado: (2015)

P994: HEDGEHOG PATHWAY INVOLVEMENT IN MASTOCYTOSIS DEVELOPMENT
por: Polivka, L., et al.
Publicado: (2022)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

P1038: CLINICOPATHOLOGIC AND MOLECULAR CORRELATES OF ORGAN DAMAGE ACROSS THE SPECTRUM OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Liang, E., et al.
Publicado: (2022)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

P1006: NEXT GENERATION SEQUENCING (NGS) IN PEDIATRIC MASTOCYTOSIS
por: Angi, A., et al.
Publicado: (2022)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
por: George, T., et al.
Publicado: (2022)

PD34 - Childhood mastocytosis: serum baseline total tryptase levels and extent of cutaneous disease as predictors of mast cell mediator release symptoms
por: Chatzipetrou, Alexia, et al.
Publicado: (2014)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

Case Report: Treatment of systemic mastocytosis with sunitinib
por: Molderings, Gerhard J., et al.
Publicado: (2017)

A Case of Systemic Mastocytosis Diagnosed Endoscopically
por: Tagliaferri, Ariana R, et al.
Publicado: (2022)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

P691: MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS
por: Wang, Yu-Hung, et al.
Publicado: (2023)

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Precision Medicine in Systemic Mastocytosis
por: Nicolosi, Maura, et al.
Publicado: (2021)

Systemic Lymphadenopathic Mastocytosis with Eosinophilia
por: Im, Soyoung, et al.
Publicado: (2022)

1551. Cat Scratch Disease as a Mimicker of Malignancy: Rare and Elusive
por: Dhal, Udit, et al.
Publicado: (2020)

P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE
por: Filipponi, V., et al.
Publicado: (2022)

Educational Case: Systemic Mastocytosis with an Associated Hematological Neoplasm
por: Mai, Brenda, et al.
Publicado: (2020)

Recent advances in diagnosis and therapy in systemic mastocytosis
por: Lee, Hyun Jung
Publicado: (2023)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

P1017: HARBOR: A PHASE 2/3 STUDY OF BLU-263 IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS AND MONOCLONAL MAST CELL ACTIVATION SYNDROME
por: Castells, M., et al.
Publicado: (2022)

Systemic mastocytosis – a diagnostic challenge
por: Lladó, Ana Cristina Amorim Oliveira Gaia, et al.
Publicado: (2014)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Systemic Mastocytosis: Radiological Point of View
por: Leone, Antonio, et al.
Publicado: (2021)

New Insights into the Pathogenesis of Systemic Mastocytosis
por: Li, Zhixiong
Publicado: (2021)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

Target Therapies for Systemic Mastocytosis: An Update
por: Sciumè, Mariarita, et al.
Publicado: (2022)

Skin and bones: systemic mastocytosis and bone
por: Wang, Mawson, et al.
Publicado: (2023)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qbo94n32o68kup3cr9d1o6vjff